


Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A pharmaceutical preparation comprising at least one compound of the general formula (I)



wherein R is a straight-chain or branched alkyl residue having 1 – 30 carbon atoms, a straight-chain or branched alkenyl residue having 2 – 30 carbon atoms, a monocyclic or polycyclic alkyl residue having 3 – 30 carbon atoms, a monocyclic or polycyclic alkenyl residue having 4-30 carbon atoms, or a monocyclic or polycyclic aromatic residue having 6-30 carbon atoms, these residues being optionally substituted by one or several substituents and a pharmaceutically compatible inert carrier or diluent.

2. (Original) The pharmaceutical preparation according to claim 1, wherein in the compound of formula (I) R is a straight chain C1-14 alkyl residue or a C3-14 cycloalkyl residue each.

3. (Previously presented) The pharmaceutical preparation according to claim 1, in the compound of formula (I) wherein R is CH_3CH_2 , isopropyl, $\text{CH}_2\text{CH}_2\text{OH}$, $\text{CH}_2\text{CH}_2\text{CH}_2\text{OH}$, or $\text{CH}_2(\text{CH}_2)_2\text{CH}_2\text{OH}$.

4. (Currently amended) The pharmaceutical preparation according to claim 1, wherein the compound of formula (I), is Bis(O-cyclohexyl-dithiocarbonato)palladium(II), Bis(O-isopropyl-dithiocarbonato)palladium(II), Bis(O-ethyl-dithiocarbonato)palladium(II), Bis(O-(2-methyl)-butyl-dithiocarbonato)palladium(II), Bis(O-butyl-dithiocarbonato)palladium(II),

Bis(O-hexyl-dithiocarbonato) palladium(II) or Bis(O-methyl)-dithiocarbonato) palladium(II).

5. (Previously presented) The pharmaceutical preparation according to claim 1, comprising additionally an immunosuppressive compound selected from the group consisting of cyclosporine, rapamycin, 15-deocyspergualine, OKT3 and azathioprine.
6. (Previously presented) The pharmaceutical preparation according to claim 1, comprising additionally cytokines, interferon or other cytostatic agents.
7. (Previously presented) The pharmaceutical preparation according to claim 1, provided in a unit dosage form for administration to a mammal which requires treatment with an anticancer or anti-autoimmunic agent.
8. (Cancelled)
9. (Currently amended) A method for the treatment of cancerous disease comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical preparation according to claim 1.
10. (Currently amended) The method according to claim 9, wherein the cancerous disease is ~~the~~ parvocellular bronchial carcinoma or colorectal carcinoma.
11. (Currently amended) A method for the treatment of a ~~cancerous disease~~ an autoimmune disease comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical preparation according to claim 1.
12. (Currently amended) A process for the production of a pharmaceutical preparation according to claim 1, comprising mixing ~~wherein~~ the compound according to formula (I) ~~is mixed~~ with a pharmaceutically compatible carrier or diluent.